CLAIMS

- 1. An isolated molecule comprising an antibody variable region which specifically binds to an extracellular domain of a TEM 7. protein selected from the group consisting of: 1, 9, 17, 19, and 44, as shown in SEQ ID NO: 196, 212, 230, 232, and 271 respectively.
- 2. The isolated molecule of claim 1 which is an in tact antibody molecule.
- 3. The isolated molecule of claim 1 which is a single chain variable region (ScFv).
- 4. The isolated molecule of claim 1 which is a monoclonal antibody.
- 5. The isolated molecule of claim 1 which is a humanized antibody.
- 6. The isolated molecule of claim 1 which is a human antibody.
- 7. The isolated molecule of claim 1 which is bound to a cytotoxic moiety.
- 8. The isolated molecule of claim 1 which is bound to a therapeutic moiety.
- 9. The isolated molecule of claim 1 which is bound to a detectable moiety.
- 10. The isolated molecule of claim 1 which is bound to an anti-tumor agent.
- 11. A method of inhibiting neoangiogenesis, comprising:

administering to a subject in need thereof an effective amount of an isolated molecule comprising an antibody variable region which specifically binds to an extracellular domain of a TEM protein selected from the group consisting of: 1, 9, 17, 19, 22, and 44, as shown in SEQ ID NO: 196, 212, 230, 232, 238, and 271, respectively, whereby neoangiogenesis is inhibited.

- 12. The method of claim 11 wherein the subject bears a vascularized tumor.
- 13. The method of claim 11 wherein the subject has polycystic kidney disease.
- 14. The method of claim 11 wherein the subject has diabetic retinopathy.
- 15. The method of claim 11 wherein the subject has rheumatoid arthritis.
- 16. The method of claim 11 wherein the subject has psoriasis.
- 17. A method of inhibiting tumor growth, comprising:

administering to a human subject bearing a tumor an effective amount of an isolated molecule comprising an antibody variable region which specifically binds to an extracellular domain of a TEM protein selected from the group consisting of: 1, 9, 17, 19, 22, and 44, as shown in SEQ ID NO: (196, 212, 230, 232, 238, and 271, respectively, whereby growth of the tumor is inhibited.